Regis Management CO LLC Has $209,000 Stake in DURECT Corporation (DRRX)
Regis Management CO LLC maintained its stake in DURECT Corporation (NASDAQ:DRRX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 134,250 shares of the specialty pharmaceutical company’s stock at the end of the 2nd quarter. Regis Management CO LLC owned about 0.09% of DURECT Corporation worth $209,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in DRRX. Tower Research Capital LLC TRC purchased a new position in shares of DURECT Corporation during the first quarter worth about $118,000. Voya Investment Management LLC increased its position in shares of DURECT Corporation by 22.8% during the second quarter. Voya Investment Management LLC now owns 82,826 shares of the specialty pharmaceutical company’s stock worth $129,000 after purchasing an additional 15,394 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of DURECT Corporation during the first quarter worth about $147,000. State of Wisconsin Investment Board purchased a new stake in shares of DURECT Corporation in the 2nd quarter valued at about $151,000. Finally, Rhumbline Advisers lifted its holdings in shares of DURECT Corporation by 12.0% in the 2nd quarter. Rhumbline Advisers now owns 175,604 shares of the specialty pharmaceutical company’s stock valued at $274,000 after purchasing an additional 18,871 shares during the last quarter. 45.82% of the stock is owned by hedge funds and other institutional investors.
Shares of DURECT Corporation (NASDAQ:DRRX) traded down 1.190% during midday trading on Wednesday, hitting $2.075. 381,095 shares of the stock were exchanged. The company’s market cap is $305.02 million. DURECT Corporation has a 12-month low of $0.74 and a 12-month high of $2.17. The firm has a 50-day moving average price of $1.66 and a 200-day moving average price of $1.38.
DURECT Corporation (NASDAQ:DRRX) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.02). DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%. The business had revenue of $4.32 million during the quarter, compared to analyst estimates of $5.17 million. On average, equities analysts predict that DURECT Corporation will post ($0.21) EPS for the current year.
DRRX has been the topic of several research analyst reports. ValuEngine raised DURECT Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. Stifel Nicolaus raised DURECT Corporation from a “hold” rating to a “buy” rating and increased their price objective for the company from $1.25 to $3.00 in a report on Wednesday, July 12th. Finally, HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of DURECT Corporation in a research report on Sunday, June 25th.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/04/regis-management-co-llc-has-209000-stake-in-durect-corporation-drrx.html.
DURECT Corporation Profile
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Want to see what other hedge funds are holding DRRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DURECT Corporation (NASDAQ:DRRX).
Receive News & Stock Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related stocks with our FREE daily email newsletter.